Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | APAF1 | O14727 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20322838 | 1.00 | KDM4E (0.51) | KDM4EAPAF1POLBMAPTRECQL | |
| SCHEMBL27505056 | 0.86 | PPARG (0.46) | KDM4EAPAF1POLBMAPTRECQL | |
| SCHEMBL8520662 | 0.86 | APAF1 (0.59) | KDM4EAPAF1POLBMAPTRECQL | |
| SCHEMBL13235820 | 0.85 | ALDH1A1 (0.44) | KDM4EPPARGPPARAALDH1A1MEN1 | |
| SCHEMBL28297815 | 0.84 | ALDH1A1 (0.47) | KDM4EPPARGPPARAALDH1A1SLC1A2 | |
| SCHEMBL27644362 | 0.82 | PPARG (0.43) | KDM4EAPAF1POLBMAPTRECQL | |
| SCHEMBL27728237 | 0.82 | TSHR (0.46) | KDM4EPOLBPPARGPPARAALDH1A1 | |
| SCHEMBL7274320 | 0.81 | CYP1A2 (0.55) | KDM4EPPARGPPARAALDH1A1MEN1 | |
| SCHEMBL20341737 | 0.81 | KMT2A (0.49) | KDM4EPOLBPPARGPPARAALDH1A1 | |
| SCHEMBL11737506 | 0.80 | PPARG (0.49) | KDM4EPPARGPPARAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3305900-B1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2021-07-21 | — | — | EP | disclosed |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-2341140-B1 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION AS (DK) | 2017-07-19 | — | — | EP | disclosed |
| EP-1021402-B1 | AROMATIC C16-C20-SUBSTITUTED TETRAHYDRO PROSTAGLANDINS USEFUL AS FP AGONISTS | UNIV DUKE (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1082299-B1 | C11 OXYMYL AND HYDROXYLAMINO PROSTAGLANDINS USEFUL AS MEDICAMENTS | UNIV DUKE (US) | 2004-06-30 | — | — | EP | disclosed |
| US-6410780-B1 | BONE DISORDERS; VISION DEFECTS | THE PROCTER & GAMBLE CO. | 2002-06-25 | — | — | US | disclosed |
| EP-1082299-A1 | C11 OXYMYL AND HYDROXYLAMINO PROSTAGLANDINS USEFUL AS MEDICAMENTS | THE PROCTER & GAMBLE COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| US-6107338-A | BONE DISORDERS; GLAUCOMA | THE PROCTER & GAMBLE COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
| EP-1021402-A1 | AROMATIC C16-C20-SUBSTITUTED TETRAHYDRO PROSTAGLANDINS USEFUL AS FP AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999050241-A1 | C11 OXYMYL AND HYDROXYLAMINO PROSTAGLANDINS USEFUL AS MEDICAMENTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999012896-A1 | AROMATIC C16-C20-SUBSTITUTED TETRAHYDRO PROSTAGLANDINS USEFUL AS FP AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | KDM4E 608/4885APAF1 546/4885POLB 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.